Pipeline

August 19, 2019

Company	Drug/Device	Medical Condition	Status
Coordination Pharmaceuticals Inc.	CPI-200	advanced tumors	Phase 1 trial initiated enrolling 27 subjects
Rimo Therapeutics Inc.	RiMO-301	advanced tumors	Phase 1 trial initiated enrolling 18 subjects
CStone Pharmaceuticals	BLU-667	RET-altered non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC) and other advanced solid tumors	Phase 1 trial initiated
Bio-Thera Solutions, Ltd.	BAT2506	rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis (AS) and ulcerative colitis	Phase 1 trial initiated enrolling 182 healthy volunteers
Mallinckrodt plc	MNK-6106 (L-ornithine phenylacetate)	hepatic (liver) cirrhosis and hepatic encephalopathy (HE)	Phase 2a trial initiated enrolling 48 adult male and non-pregnant female subjects with hepatic cirrhosis who have a history of at least two or more documented episodes of HE in the last 12 months – with one in the last six months – and who present with hyperammonemia at the time of screening
Kedrion Biopharma	10 percent intravenous immunoglobulin	primary immunodeficiency diseases (PI)	Phase 3 trial initiated enrolling 50 subjects at 16 sites in the U.S.
binx health	binx io (first-of-kind, highly sensitive and specific, molecular point-of-care (POC) diagnostic testing platform)	chlamydia (CT) and gonorrhea (NG)	510(k) clearance granted by the FDA
Regeneron Pharmaceuticals, Inc.	EYLEA (aflibercept) Injection 2 mg, single-dose, sterilized prefilled syringe	multiple retinal diseases, including wet age-related macular degeneration and diabetic eye diseases	Approval granted by the FDA
TB Alliance	Pretomanid Tablets in combination with bedaquiline and linezolid	Extensively Drug-Resistant Tuberculosis (XDR-TB) and treatment intolerant/non-responsive Multidrug-Resistant (MDR) TB	Approval granted by the FDA